Portola's Factor Xa antidote has first Phase III "breakthrough"
This article was originally published in Scrip
Executive Summary
The Portola Pharmaceuticals Factor Xa inhibitor antidote andexanet alfa immediately and significantly reversed the anticoagulation effect of Pfizer's and Bristol-Myers Squibb's Eliquis (apixaban) in the first of several Phase III clinical trials.